The Canadian Press - ONLINE EDITION

FDA approves new Cubist antibiotic for skin infections commonly found in hospitals

  • Print

WASHINGTON - The Food and Drug Administration on Friday approved a new antibiotic from Cubist Pharmaceuticals to treat common skin infections often acquired in the hospital.

Regulators cleared the company's Sivextro as a pill and as an intravenous solution for adults with skin infections caused by bacteria that are often resistant to older antibiotics.

It's the second FDA approval in less than a month for a new antibiotic to treat such infections. In late May, the FDA approved a similar drug from Durata Therapeutics Inc.

Antibiotics like penicillin and streptomycin first became widely available in the 1940s, and today dozens are still used to kill or suppress the bacteria behind illnesses ranging from strep throat to urinary-tract infections. The drugs are considered one of the greatest advances in the history of medicine, and have saved countless lives.

But in recent decades some common bacteria have grown resistant to antibiotics that were once highly effective. Experts say overuse and misuse of the drugs by physicians has contributed to the rise of these so-called superbugs.

The FDA gave Sivextro an expedited review under a 2012 law designed to encourage drugmakers to invest in researching and development of new antibiotics. Under the measure, Cubist will receive an additional five years of exclusive marketing rights to the drug.

Sivextro is designed to be taken over six days as a daily intravenous infusion or as a tablet. Cubist says the oral form of the drug gives patients the option of completing therapy at home, which could cut down on hospital-stay costs.

The drug works against a variety of common bacteria, including Staphylococcus aureus, Streptococcus species and Enterococcus faecalis.

The Centers for Disease Control and Prevention estimated last year that the staph infection methicillin-resistant Staphylococcus aureus, or MRSA, kills about 11,000 people annually.

The most common side effects seen in company studies were nausea, headache, diarrhea, vomiting and dizziness.

Lexington, Massachusetts-based Cubist gets over 80 per cent of its revenue from a single product: the antibiotic Cubicin, which is used to treat infections of the skin and blood. Last fall the company paid $1.24 billion to acquire rival drugmakers Trius Therapeutics and Optimer Pharmaceuticals Inc., both developers of antibiotics.

Shares of Cubist Pharmaceuticals Inc. rose $1.26, or 1.7 per cent, to $73.50 in afterhours trading Friday.

Fact Check

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories?
Please use the form below and let us know.

* Required
  • Please post the headline of the story or the title of the video with the error.

  • Please post exactly what was wrong with the story.

  • Please indicate your source for the correct information.

  • Yes

    No

  • This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.

  • Cancel

Having problems with the form?

Contact Us Directly
  • Print

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

Have Your Say

Comments are open to Winnipeg Free Press print or e-edition subscribers only. why?

Have Your Say

Comments are open to Winnipeg Free Press Subscribers only. why?

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.

letters

Make text: Larger | Smaller

LATEST VIDEO

Weather for final Fringing weekend

View more like this

Photo Store Gallery

  • A Yellow-bellied Sapsucker hangs out on a birch tree in St. Vital. The Yellow-bellied Sapsucker is considered a keystone species. Other species take advantage of the holes that the birds make in trees. A group of sapsuckers are collectively known as a
  • July 1, 2012 - 120701  -   Canada Day fireworks at The Forks from the Norwood Bridge Sunday, July 1, 2012.    John Woods / Winnipeg Free Press

View More Gallery Photos

Poll

Will higher pork prices change your grocery-shopping habits?

View Results

View Related Story

Ads by Google